X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (119) 119
omalizumab (119) 119
asthma (87) 87
antiimmunoglobulin-e therapy (79) 79
asthma - drug therapy (79) 79
index medicus (78) 78
allergy (70) 70
anti-asthmatic agents - therapeutic use (65) 65
antibodies, monoclonal, humanized (61) 61
antibodies, monoclonal - therapeutic use (58) 58
efficacy (55) 55
severe allergic-asthma (51) 51
antibodies, anti-idiotypic (49) 49
severe persistent asthma (49) 49
antiimmunoglobulin-e antibody (48) 48
immunology (48) 48
quality-of-life (45) 45
anti-ige antibody (44) 44
male (43) 43
female (42) 42
tolerability (40) 40
adult (39) 39
asthma - immunology (38) 38
immunoglobulin e - immunology (38) 38
anti-ige (37) 37
antibodies, anti-idiotypic - therapeutic use (36) 36
ige (36) 36
immunoglobulin e (36) 36
treatment outcome (36) 36
fc-epsilon-ri (35) 35
respiratory system (35) 35
child (34) 34
drug therapy (33) 33
long-term control (33) 33
middle aged (32) 32
exacerbations (30) 30
monoclonal-antibody (29) 29
adolescent (26) 26
antibodies, monoclonal, humanized - therapeutic use (26) 26
anti-asthmatic agents - adverse effects (25) 25
quality of life (24) 24
aged (23) 23
asthma - physiopathology (23) 23
antibodies, monoclonal - adverse effects (22) 22
pharmacology & pharmacy (22) 22
safety (22) 22
anti-allergic agents - therapeutic use (21) 21
monoclonal antibodies (21) 21
allergies (20) 20
randomized controlled trials as topic (20) 20
severity of illness index (20) 20
inflammation (19) 19
add-on therapy (18) 18
humanized monoclonal-antibody (18) 18
medicine, general & internal (18) 18
rhinitis (18) 18
animals (17) 17
antiimmunoglobulin-e (17) 17
adrenal cortex hormones - therapeutic use (16) 16
clinical trials (16) 16
hypersensitivity - drug therapy (15) 15
anti-asthmatic agents - administration & dosage (14) 14
omalizumab - therapeutic use (14) 14
allergic asthma (13) 13
care and treatment (13) 13
chronic idiopathic urticaria (13) 13
clinical trials as topic (13) 13
hypersensitivity - immunology (13) 13
immunotherapy (13) 13
medicine, research & experimental (13) 13
children (12) 12
therapy (12) 12
allergic-asthma (11) 11
allergy and immunology (11) 11
antibodies, anti-idiotypic - adverse effects (11) 11
antibodies, monoclonal - pharmacology (11) 11
asthma - therapy (11) 11
corticosteroids (11) 11
drug therapy, combination (11) 11
e therapy (11) 11
immunoglobulin e - blood (11) 11
immunoglobulin-e (11) 11
patients (11) 11
severe asthma (11) 11
adrenal cortex hormones - administration & dosage (10) 10
antibodies, monoclonal - administration & dosage (10) 10
antibodies, monoclonal, humanized - administration & dosage (10) 10
chronic disease (10) 10
medical research (10) 10
allergic rhinitis (9) 9
anti-asthmatic agents - pharmacology (9) 9
antibodies, monoclonal, humanized - adverse effects (9) 9
asthma - diagnosis (9) 9
asthma - etiology (9) 9
childhood asthma (9) 9
cost-effectiveness (9) 9
double-blind (9) 9
placebo-controlled trial (9) 9
pulmonary and respiratory medicine (9) 9
retrospective studies (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Allergy, ISSN 0105-4538, 03/2005, Volume 60, Issue 3, pp. 309 - 316
Background: Patients with severe persistent asthma who are inadequately controlled despite Global Initiative for Asthma (GINA) 2002 step 4 therapy are a... 
omalizumab | Global Initiative for Asthma 2002 step 4 therapy | severe persistent asthma | exacerbations | anti-immunoglobulin E | anti‐immunoglobulin E | Omalizumab | Anti-immunoglobulin E | Exacerbations | Global initiative for asthma 2002 step 4 therapy | Severe persistent asthma | POPULATION | MULTICENTER | RISK-FACTORS | EFFICACY | SEVERE ALLERGIC-ASTHMA | IMMUNOLOGY | ANTIIMMUNOGLOBULIN-E ANTIBODY | LONG-TERM CONTROL | ALLERGY | TOLERABILITY | QUALITY-OF-LIFE | ANTI-IGE ANTIBODY | Anti-Asthmatic Agents - adverse effects | Anti-Asthmatic Agents - therapeutic use | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Receptors, Adrenergic, beta-2 - drug effects | Adrenal Cortex Hormones - therapeutic use | Dose-Response Relationship, Drug | Forced Expiratory Volume | Antibodies, Monoclonal, Humanized | Adult | Female | Adrenergic beta-Agonists - therapeutic use | Drug Therapy, Combination | Severity of Illness Index | Asthma - physiopathology | Double-Blind Method | Administration, Inhalation | Treatment Outcome | Asthma - drug therapy | Retreatment | Adolescent | Quality of Life | Aged | Patient Admission - statistics & numerical data | Antibodies, Anti-Idiotypic | Adrenal Cortex Hormones - administration & dosage | Respiratory therapy | Initiatives | Medical treatment | Asthma
Journal Article
Clinical and Translational Allergy, ISSN 2045-7022, 07/2018, Volume 8, Issue 1, pp. 1 - 8
Journal Article
CURRENT DRUG TARGETS, ISSN 1389-4501, 2015, Volume 16, Issue 2, pp. 171 - 178
The humanized monoclonal anti-IgE antibody omalizumab is currently the only biologic drug approved for asthma treatment. Omalizumab inhibits allergic responses... 
COST-EFFECTIVENESS | BRONCHIAL EPITHELIAL-CELLS | SEVERE PERSISTENT | SEVERE ALLERGIC-ASTHMA | MONOCLONAL-ANTIBODY | TO-TREAT ASTHMA | HIGH-AFFINITY RECEPTOR | ADD-ON THERAPY | Anti-IgE | ANTIIMMUNOGLOBULIN-E THERAPY | severe asthma | PHARMACOLOGY & PHARMACY | omalizumab | UNCONTROLLED ASTHMA
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 1, Issue 1, p. CD003559
Journal Article
Journal Article